

## **PRESS RELEASE**

## Monthly information regarding the total number of voting rights and shares comprising the Company's share capital

Article L.233-8 II of the French Code of Commerce Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers)

Date	Total number of shares	Number of voting rights - GROSS**	Number of voting rights - NET
April 30, 2016	13,836,292*	18,689,123	18,648,227

<sup>\*</sup> Since the implementation of this equity facility contract signed with Societe Generale on October 22, 2015, 250,000 new shares have been issued for a gross total of €642,000, i.e. at an average price of €2.57.

Next publication: 2016 Q2 revenue, July 12, 2016 (after the market closes)

## **About Safe Orthopaedics:**

Founded in 2010, Safe Orthopaedics is a French medical technology company that develops and markets an innovative range of sterile implants and associated single-use surgical instruments, with the aim of facilitating safer, optimized and lower-cost spinal surgery. By avoiding the reuse of surgical instruments, Safe Orthopaedics reduces the risk of infection, avoids the cumbersome and unreliable logistics of instrument sterilization, and limits hospital costs. Protected by 17 patent families, the SteriSpine™ Kits are CE-marked and FDA cleared; they are already being marketed in 16 countries, in Europe and the United States. The company is based at Eragny-sur-Oise (France), and has 33 employees and a US subsidiary.

For more information, visit: www.SafeOrtho.com

## **Contacts**

Thierry Lambert

CFO

Safe Orthopaedics NewCap

Yves Vignancour Julien Perez / Valentine Brouchot
CEO Investor Relations

Nicolas Merigeau *Media Relations* 

Tel.: +33 (0)1 34 21 50 00 Tel.: +33 (0)1 44 71 94 94 investors@safeorthopaedics.com SafeOrtho@newcap.eu



<sup>\*\*</sup> total number of voting rights calculated on the basis of all shares to which voting rights are attached, including those that do not have voting rights.